Publicacións nas que colabora con Adolfo Figueiras Guzmán (24)

2024

  1. Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study

    Revista Espanola de Cardiologia, Vol. 77, Núm. 7, pp. 539-546

  2. Outpatient glucocorticoid use and COVID-19 outcomes: a population-based study

    Inflammopharmacology, Vol. 32, Núm. 4, pp. 2305-2315

  3. The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study

    Inflammopharmacology

2023

  1. Colchicine and risk of hospitalization due to COVID-19: A population-based study

    Journal of Medical Virology, Vol. 95, Núm. 2

  2. Effect of Previous Anticoagulant Treatment on Risk of COVID-19

    Drug Safety, Vol. 46, Núm. 3, pp. 273-281

  3. Outpatient atorvastatin use and severe COVID-19 outcomes: A population-based study

    Journal of Medical Virology, Vol. 95, Núm. 7

  4. RE: Colchicine and risk of hospitalization due to COVID-19: A population-based study

    Journal of Medical Virology

  5. Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study

    European Neuropsychopharmacology, Vol. 71, pp. 96-108

2022

  1. Impact on In- and Out-of-Hospital Drug Prescriptions of Including a More Expensive Me-Too Antidepressant in a Hospital Drug Formulary: a Controlled Longitudinal Study

    Pharmacoepidemiology and Drug Safety, Vol. 31, Núm. 5, pp. 556-565

2020

  1. Impact of a change of bronchodilator medications in a hospital drug formulary on intra- A nd out-of-hospital drug prescriptions: Interrupted time series design with comparison group

    Implementation Science, Vol. 15, Núm. 1

  2. Impact of a health alert and its implementation on flutamide prescriptions for women: an interrupted time series analysis

    BMC health services research, Vol. 20, Núm. 1, pp. 597

2019

  1. Computerized Clinical Decision Support Systems and Antibiotic Prescribing: A Systematic Review and Meta-analysis

    Clinical Therapeutics, Vol. 41, Núm. 3, pp. 552-581

  2. Impact of removal and restriction of me-too medicines in a hospital drug formulary on in- and outpatient drug prescriptions: interrupted time series design with comparison group

    Implementation science : IS, Vol. 14, Núm. 1, pp. 75

  3. Pharmaceutical companies information and antibiotic prescription patterns: A follow-up study in Spanish primary care

    PLoS ONE, Vol. 14, Núm. 8

2018

  1. Impact of Health Authority Control Measures Aimed at Reducing the Illicit Use of Anabolic-Androgenic Steroids

    European Addiction Research, Vol. 24, Núm. 1, pp. 28-36

2017

  1. Trends in celecoxib and etoricoxib prescribing following removal of prior authorization requirement in Spain

    Journal of Clinical Pharmacy and Therapeutics, Vol. 42, Núm. 2, pp. 185-188

2014

  1. Inappropriate prescribing according to the STOPP/START criteria in older people from a primary care setting

    European Journal of General Practice, Vol. 20, Núm. 4, pp. 281-289

2013

  1. Valoración de la idoneidad de los criterios STOPP/START en el ámbito de atención primaria en España por el método RAND

    Semergen: revista española de medicina de familia, Núm. 8, pp. 413-420

2012

  1. Impact of a health safety warning and prior authorisation on the use of piroxicam: A time-series study

    Pharmacoepidemiology and Drug Safety, Vol. 21, Núm. 3, pp. 281-284

2010

  1. Case-crossover analysis of air pollution health effects: A systematic review of methodology and application

    Environmental Health Perspectives, Vol. 118, Núm. 8, pp. 1173-1182